However, of the 12 tumors analyzed, 9 contain putative chromothripsis sites, which indicates that perhaps 31% (9/29) of GBMs are impacted by the phenomenon, which is consistent with the findings of Malhotra et al. Our current analysis highlights several distinct tumor mutational schemes that result in the Ras/Raf/MEK/ERK signaling pathway activation, TP53 ablation, and RB1 inhibition in RTK-amplified GBMs. The gene discussed is RB1; the disease is neoplasm.